Transforming CLL care: measurable residual disease (MRD) guided stopping, smart triplet selection, and next‑gen Bruton tyrosine kinase (BTKs)—practical insights.
 
Credit available for this activity expires: 02/19/27

Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/chronic-lymphocytic-leukemia-cll-review-combination-2026a10004ku?ecd=bdc_podcast_libsyn_mscpedu